Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Metformin and dapagliflozin effects on epicardial adipose tissue area in prediabetes and type 2 diabetes patients : MRI evaluation studies

Tools
- Tools
+ Tools

Al-Talabany, S., Weir-McCall, J., Mohan, Mohapradeep, Singh, J., Mordi, I., Gandy, S., Khan, F., Choy, A.M., Houston, G., Pearson, E., George, J., Struthers, A. and Lang, C. (2018) Metformin and dapagliflozin effects on epicardial adipose tissue area in prediabetes and type 2 diabetes patients : MRI evaluation studies. In: World Congress of Cardiology & Cardiovascular Health 2018. Published in: Global Heart, 13 (4). p. 392. ISSN 2211-8179. doi:10.1016/j.gheart.2018.09.060

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1016/j.gheart.2018.09.060

Request Changes to record.

Abstract

397421) (n=56 patients ,mean age 67 ± 7 y; mean BMI 32.5± 5.3 kg/m2) with chronic heart failure and type 2 diabetes who received either dapagliflozin (10mg/day) or placebo for 12 months respectively.

Results:
Metformin treatment in the METREMODEL trial reduced body weight significantly by 4.2kgs (p=0.001).but did not reduce EAT area (metformin -0.1 ± 3.8 cm2 vs. placebo -0.5 ± 2.9 cm2 p= 0.7). In the REFORM trial, dapagliflozin reduced body weight significantly by -1.9 kg (p= 0.054) with no significant reduction in EAT area (dapagliflozin -1.00 ± 3.6 cm2 vs. placebo -0.7 ± 3.1 p=0.8).

Conclusion:
In prediabetes and type 2 diabetes, we found that metformin and dapagliflozin treatment resulted in significant weight loss but had no significant effect on EAT. Our findings suggest that the reported cardiovascular benefits of these two diabetic therapies are not likely to be mediated by effects on EAT.

Item Type: Conference Item (Paper)
Divisions: Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School > Health Sciences > Mental Health and Wellbeing
Faculty of Medicine > Warwick Medical School
Journal or Publication Title: Global Heart
Publisher: Elsevier
ISSN: 2211-8179
Official Date: December 2018
Dates:
DateEvent
December 2018Published
26 October 2018Accepted
Volume: 13
Number: 4
Page Range: p. 392
DOI: 10.1016/j.gheart.2018.09.060
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access
Conference Paper Type: Paper
Title of Event: World Congress of Cardiology & Cardiovascular Health 2018
Type of Event: Conference

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us